Document Detail


NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model.
MedLine Citation:
PMID:  19664667     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
NAPVSIPQ (NAP) is a small, active fragment of activity-dependent neuroprotective protein that has neuroprotective and memory enhancing properties at very low concentrations. Previous research demonstrated that 1-2 weeks of treatment provided memory enhancing effects in normal middle-aged and cholinergically lesioned rats. Improvement in cognitive performance was shown in 12-month-old C57Bl6/J mice after 10 days of oral treatment with D-NAP and D-SALLRSIPA. Additionally, NAP-related cognitive benefits on spatial memory were observed in a 3xTg Alzheimer mouse model after 6 months of chronic administration at a moderate stage of disease. In this study, the potential memory enhancing effect of NAP was investigated using the APP23 transgenic mouse model for Alzheimer's disease. Twelve-month-old male heterozygous APP23 mice and their wild-type control littermates were intraperitoneally injected with 0.3 microg NAP/g body weight or with saline vehicle for 22 consecutive days. Cognitive performance training in the Morris Water Maze (MWM) started on day 8 of treatment. The internal validity of our study was demonstrated by the fact that the APP23 mice performed significantly worse in the MWM than wild-type animals. Treatment with NAP, however, did not exert any significant effects on MWM performance. Although we failed to show significant memory enhancing effects in this study, NAP might be a promising peptide for disease-modifying therapy in neurodegenerative disease, but short-term effects are probably not to be expected. Also, most likely, treatment should start in an early stage, i.e. before full-blown pathology is eminent, and the necessary treatment period should enclose several months.
Authors:
A Van Dijck; D Van Dam; P P De Deyn
Related Documents :
24292207 - Diosgenin-induced cognitive enhancement in normal mice is mediated by 1,25d3-marrs.
20371377 - Alteration of working memory but not in anxiety or stress response in p300/cbp associat...
18706097 - Kihi-to, a herbal traditional medicine, improves abeta(25-35)-induced memory impairment...
15858837 - Mice lacking the adenosine a1 receptor have normal spatial learning and plasticity in t...
22506977 - Control-display mapping in brain-computer interfaces.
15458587 - Relationship of local infarctions to cognitive and psychosocial impairments after aneur...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-08-05
Journal Detail:
Title:  Peptides     Volume:  30     ISSN:  1873-5169     ISO Abbreviation:  Peptides     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-25     Completed Date:  2010-02-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8008690     Medline TA:  Peptides     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2480-2     Citation Subset:  IM    
Affiliation:
Laboratory of Neurochemistry & Behavior, Institute Born-Bunge, Dept Biomedical Sciences, University of Antwerp, Belgium. Annemie.vandijck@ua.ac.be
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease / drug therapy*,  pathology
Animals
Disease Models, Animal
Male
Memory / drug effects*
Mice
Neuroprotective Agents / pharmacology*,  therapeutic use*
Oligopeptides / pharmacology*,  therapeutic use*
Chemical
Reg. No./Substance:
0/NAPVSIPQ peptide; 0/Neuroprotective Agents; 0/Oligopeptides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Skeletal contributions to plasma CNP forms: Evidence from regional sampling in growing lambs.
Next Document:  Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid l...